Clinical Trials Browser

molibresib × Clear all

NCT02964507 2024-08-29

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Phase 1 Terminated

124 enrolled 23 charts

Breast Neoplasms, Neoplasms

NCT03925428 2020-09-28

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

Phase 1 Withdrawn

GastrointestinalLymphoid

Lymphoma, Pancreatic Neoplasms, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT04116359 2020-09-28

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

Phase 1/2 Withdrawn

Metastatic NUT Carcinoma

NCT03702036 2020-04-13

Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma

No longer available

Other solid neoplasm

Solid Tumours

NCT01587703 2020-03-16

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

Phase 1 Completed

196 enrolled 78 charts

CNSPlasma cellThoracic

Carcinoma, Multiple Myeloma, Neoplasms, Neuroblastoma, Small Cell Lung Carcinoma